

VANDERBILT TULLAHOMA-HARTON HOSPITAL ANTIBIOGRAM, 2024

Data represent percent of isolates susceptible, from December 2022-November 2023; One isolate per patient only

Organism	N	Amikacin	Amoxicillin-clavulanate	Ampicillin	Ampicillin-sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ertapenem	Gentamicin	Levofloxacin	Meropenem	Nitrofurantoin	Piperacillin-tazobactam	Tobramycin	Trimethoprim-sulfamethoxazole
<i>Enterobacter cloacae</i>	40	100				83		90	78	70	78	98	88	100	23	78	98	83
<i>Escherichia coli</i>	451	100	87	54	80	90	87	91	91	90	100	92	72	100	97	98	91	77
<i>Klebsiella pneumoniae</i>	127	100	87		74	87	84	87	89	86	100	93	86	100	47	86	89	83
<i>Pseudomonas aeruginosa</i>	81	100				83		89	93				70	90		85	ND	
<i>Proteus mirabilis</i>	74	100	91	65	91	97	74	95	97	85	100	76	54	ND		100	77	72

Organism	N	Ampicillin	Oxacillin	Ceftaroline	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Nitrofurantoin	Penicillin	Rifampin	Tetracycline	Trimethoprim-sulfamethoxazole	Vancomycin
<i>Enterococcus faecalis</i>	144	100				96	41		81	68	100	99	99				97
<i>Staphylococcus aureus ss. aure</i>	207		55	96	80	100	91	40	97	68	100	100	19	100	83	94	100
MRSA	94			92	62	100	83	15	97	39	100	99		100	75	93	100
MSSA	114		100	100	95	100	97	61	97	90	100	100	35	100	90	96	100

Key	% Susceptibility
	< 70
	70-89
	≥ 90